LPCN Lipocine Inc.

2.34
+0.2  (+9%)
Previous Close 2.14
Open 2.14
Price To Book 5.85
Market Cap 58,135,620
Shares 24,844,282
Volume 356,314
Short Ratio
Av. Daily Volume 109,248

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. Seeking feedback from FDA regarding Phase 3 design.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Further CRL issued May 9, 2018. PDUFA date November 9, 2019.
TLANDO - LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
Phase 2 dosing to commence 3Q 2019.
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Is Lipocine (NASDAQ:LPCN) Using Too Much Debt?
  2. Lipocine Announces Second Quarter 2019 Financial and Operational Results
  3. Lipocine to Present at the Canaccord Genuity 39th Annual Growth Conference
  4. LPCN: Poster Demonstrates NASH and Free T Link
  5. Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population
  6. What Percentage Of Lipocine Inc. (NASDAQ:LPCN) Shares Do Insiders Own?
  7. 18 Stocks Joining The Russell Indices
  8. Lipocine Set To Join Russell Microcap® Index
  9. Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm?
  10. LPCN: Now We Have PDUFA Date; Target To $7
  11. Lipocine Announces TLANDO™ NDA PDUFA Action Date of November 9, 2019
  12. Lipocine: 1Q Earnings Snapshot
  13. Lipocine Announces First Quarter 2019 Financial and Operational Results
  14. Did You Manage To Avoid Lipocine's (NASDAQ:LPCN) Devastating 81% Share Price Drop?
  15. LPCN: Turning the Tables
  16. Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
  17. LPCN: ABPM Study Topline Data
  18. Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy
  19. Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
  20. Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference